BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$8.66
arrow_downward
-0.52%(-0.045) 1D
Sep 18, 11:40:39 AM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$8.60
High
$8.84
Low
$8.54
Mkt. cap
2.21B
Avg. vol.
3.85M
Volume
1.17M
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.57
Shares outstanding
255.54M
No. of employees
435
Open
$8.60
High
$8.84
Low
$8.54
Mkt. cap
2.21B
Avg. vol.
3.85M
Volume
1.17M
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.57
Shares outstanding
255.54M
No. of employees
435
News stories
From web sources and news partners
Insider Monkey
·
23 hours ago
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs
Investing.com
·
3 days ago
BioCryst at Morgan Stanley conference: pivots to external growth
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com